Want to see EVO full AI Analyst Report?
EVO Stock Chart & Stats
$3.26
-$0.25(-5.45%)
At close: 4:00 PM EST
$3.26
-$0.25(-5.45%)
Day’s Range― - ―
52-Week Range$2.31 - $4.42
Previous CloseN/A
Volume32.72K
Average Volume (3M)186.07K
Market Cap
$1.03B
Enterprise Value$839.57M
Total Cash (Recent Filing)$445.23M
Total Debt (Recent Filing)$387.87M
Price to Earnings (P/E)―
Beta1.18
Next Earnings
Aug 13, 2026EPS Estimate
0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.55
Shares Outstanding355,819,120
10 Day Avg. Volume383,647
30 Day Avg. Volume186,074
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.14
Price to Sales (P/S)1.23
P/FCF Ratio-11.82
Enterprise Value/Market Cap0.81
Enterprise Value/Revenue1.13
Enterprise Value/Gross Profit9.92
Enterprise Value/Ebitda-8.75
Forecast
1Y Price Target
$5.50Price Target Upside68.71% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)-0.41
Revenue Forecast (FY)$853.63M
Bulls Say, Bears Say
Bulls Say
Diversified R&D Services + Co-owned Asset PortfolioEvotec's integrated service model (discovery through preclinical and biologics) plus a portfolio of 100+ co-owned R&D assets creates multiple, durable revenue channels: fee-for-service work, milestone/royalty upside and EVOequity realizations. This diversification reduces single-revenue dependence and supports long-term resilience as the firm monetizes assets and scales higher-value services.
Validated Platform Partnerships And Scientific WinsRepeated awards and collaborations (Gates grants, BARDA, Almirall nomination, BMS milestone) validate Evotec's platform capabilities and scientific credibility. These long-term partnerships both underwrite recurring contracted work and increase probability of milestone payments or downstream royalties, strengthening the company's competitive moat in platform-enabled drug discovery.
Strong Liquidity And Low LeverageA net-cash position, sizable liquidity and expected ~USD100m Tubulis proceeds provide a multi-quarter runway to execute the Horizon transformation and absorb restructuring costs. Low leverage (debt/equity ~0.13) reduces refinancing risk and gives management optionality for targeted investments, M&A or further EVOequity realizations without immediate capital markets reliance.
Bears Say
Sustained Unprofitable MarginsPersistently negative operating and net margins indicate the business has yet to convert revenue into reliable profits; negative returns (ROE ~-25%) limit internal funding for growth and increase dependence on external monetizations. Structural margin recovery is required before profitability can sustain reinvestment and deliver shareholder returns.
Negative And Volatile Free Cash FlowVolatile and negative free cash flow constrains the company's ability to self-fund Horizon investments and absorb restructuring outlays. Past swings (strong FCF in 2022 vs outflows 2023–2025) imply reliance on asset sales, milestone receipts or external financing to bridge deficits, increasing execution risk over the medium term.
Revenue Volatility From Lumpy Milestones And Market SoftnessDependence on uneven license/milestone payments and exposure to early discovery market cycles makes top-line outcomes lumpy and less predictable. Large one-off items and FX swings amplify quarter-to-quarter volatility, complicating planning and making it harder to deliver stable margin expansion despite structural savings initiatives.
Evotec AG News
EVO FAQ
What was Evotec AG’s price range in the past 12 months?
Evotec AG lowest stock price was $2.31 and its highest was $4.42 in the past 12 months.
What is Evotec AG’s market cap?
Evotec AG’s market cap is $1.03B.
When is Evotec AG’s upcoming earnings report date?
Evotec AG’s upcoming earnings report date is Aug 13, 2026 which is in 42 days.
How were Evotec AG’s earnings last quarter?
Currently, no data Available
Is Evotec AG overvalued?
According to Wall Street analysts Evotec AG’s price is currently Undervalued.
Does Evotec AG pay dividends?
Evotec AG pays a Monthly dividend of $0.072 which represents an annual dividend yield of N/A. See more information on Evotec AG dividends here
What is Evotec AG’s EPS estimate?
Evotec AG’s EPS estimate is 0.01.
How many shares outstanding does Evotec AG have?
Evotec AG has 355,819,120 shares outstanding.
What happened to Evotec AG’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evotec AG?
Currently, no hedge funds are holding shares in EVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evotec AG Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$5.50 (68.71% Upside)
$5.50 (68.71% Upside)
Blogger Sentiment
Bullish
EVO Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-33.10%
12-Months-Change
Fundamentals
Return on Equity
-24.55%
Trailing 12-Months
Asset Growth
-10.07%
Trailing 12-Months
Company Description
Evotec AG
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
EVO Company Deck
EVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mixed picture: significant near-term financial weakness driven by the nonrecurrence of a large prior-year license payment, FX headwinds, negative adjusted EBITDA and substantial restructuring charges contrasted with clear strategic actions and early signs of commercial stabilization. Management initiated the Horizon transformation, added experienced leadership, pointed to improving commercial leading indicators (higher proposal activity, faster turnaround, fewer change orders and net sales orders +15% YoY), and maintained full-year guidance while highlighting expected structural savings (~EUR 75m run-rate by end-2027, with ~20–30% in 2026) and an anticipated USD 100m cash inflow in Q2. Given material near-term negatives balanced against concrete transformation moves, underlying Just momentum (ex-Sandoz) and improving D&PD indicators, the overall tone is cautious but constructive.View all EVO earnings summariesEVO Stock 12 Month Forecast
Average Price Target
$5.50
▲(68.71% Upside)
Technical Analysis
Pacira Pharmaceuticals
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Collegium Pharmaceutical
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
1.95% Other Institutional Investors
98.05% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---